Moreover, AML patients with common genetic mutations, including FLT3-ITD/TKD mutation (Supplementary Fig. S3c, P = 0.003), IDH1 mutation (Supplementary Fig. S3d, P = 0.011), NPM1 mutation (Supplementary Fig. S3e, P < 0.001) or N-RAS mutation (Supplementary Fig. S3f, P < 0.001) was significantly associated with higher expression of TNFAIP2 than those without these mutations. This evidence concerns the gene TNFAIP2 and acute myeloid leukemia.